Clinical Trials

The McDevitt laboratory is now involved in 6 clinical trials involving the programmable bio-nano-chip for major diseases in the areas of cardiac heart disease, oral cancer, ovarian cancer, prostate cancer and drugs of abuse. These translational activities are unique and place this approach in a position to make transformative changes to the US and global healthcare. John T. McDevitt has recently established the "Texas Cancer Diagnostics Pipeline" and serves at the Director for the newly formed "Early Disease Detection Gulf Coast Consortium Cluster" thereby creating a network of over 100 clinical researchers devoted to next generation of affordable diagnostics. Collectively these activities are helping to move swiftly these medical microdevices from the bench to the bedside. Read more about these bench to the bedside translational activities.


Study Sponsor Study Period Disease Area # of Participants Clinical Sites Number of Biomarkers
 Development of A Lab-on-a-Chip System for Saliva-Based Diagnostics NIDCR-U01 9/1/06 - 2/28/11 Cardiac Disease 1000 patients   15 proteins
 Monitoring of Oral Cancer Patients Using Novel Lab-on-a-Chip Ensembles NIDCR-Grand Opportunity 9/25/09 - 8/31/11  Oral Cancer 950 patients   7 celluar markers
 Texas Cancer Diagnostics Pipeline Consortium: Oral Cancer CPRIT 9/1/10 - 8/31/13 Oral Cancer 2200 patients   7 celluar markers
 Texas Cancer Diagnostics Pipeline Consortium: Ovarian Cancer CPRIT 9/1/10 - 8/31/13 Ovarian Cancer 1250 patients   4 proteins + >10 auto-antibodies
 Texas Cancer Diagnostics Pipeline Consortium: Prostate Cancer CPRIT 9/1/10 - 8/13/13 Prostate Cancer 400 patients   3 proteins
 Advanced Bio-nano-chips for Saliva Based Drug Tests at the Point of Arrest UK: Home Office 9/1/09 - 3/31/11 Drugs of Abuse 240 participants   4 drugs